expression surface markers

Slides:

Advertisements

Similar presentations

A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.

Advertisements

Counts TLR3-PE Counts TLR8-PE Counts TLR9-PE C AB Supplemental Figure 1.

Marker (%) Normal EPCs Mean ± SM (%) MMD EPCs Mean ± SM (%) CD ± ± 6.8 KDR27.3 ± ± 8.90 CD ± ± 3.93 CD ±

Supplementary figure 1 Surface marker expression in % days A B Supplementary figure 1: Characterization of dmECFC and hECFC. ECFC clones showed a typical.

Supplementary Figure 1 Supplementary Figure 1. Screen for small-molecule compounds modulating luciferase activity. Claudin-4 reporter cells were seeded.

Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D.

SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.

ShCon shNaa10p GAPDH MCL1 EPHB4 RPS6KA5 SMAD1 BFAR EIF4B CYR61 STAT5B NFkbil2 VEGFC TNFRSF1A CyclinD Supplementary Figure S1 RKO cells A B siCon siNaa10p-395siNaa10p-464siNaa10p-649.

Normal skin tissue Supplementary Fig 1A KLF4 has a tumor suppressive function in human skin cancer. Skin cancer tissues were deparaffinized and IHC was.

Supplementary Figure 1: Correlation analysis of DKC1 mRNA and dyskerin protein quantity in neuroblastoma cell lines.

A B Pax8 CK7 CA125 HE4 HE xenograft tumor primary #20 bright phase HE

Supplementary Figure 1. (A) Expression of DSB repair proteins

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

Fig. 4. Positive expression of GD2 and CD90 were significantly increased in glioblastoma multiforme (GBM) cells than neural stem cells (NSCs). BD Lyoplate.

Supplementary Figure 1 Supplementary Figure 1: ROR agonists increase the expression of a luciferase reporter driven by Gal4-ROR. In HEK293T cells, Gal4-ROR

Invest. Ophthalmol. Vis. Sci ;53(11): doi: /iovs Figure Legend:

WNT5A is a Key Regulator of the Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties in Human Gastric Carcinoma Cells Pathobiology 2013;80:

Volume 17, Issue 8, Pages (November 2016)

Qihui Pua, Ryan Spoonera, Lisa A. DeLouisea,b,*

A B Fig. 1C Fig. 2A (G007-LK) Tanaka et al. Supplementary Figure S1 -

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

A B C Supplementary figure S7

Supplementary figure S1 by Shin et al.

Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer Xiumei Zheng, Li Fan, Pengfei Zhou, Hong Ma, Shaoyi Huang, Dandan.

Supplementary Figure 1 A B C siControl siRNF31 siRNF31+siP53 siControl

Volume 5, Issue 2, Pages (October 2013)

Masanori Ono, M. D. , Ph. D. , Ping Yin, Ph. D. , Antonia Navarro, M

1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo

A B C D E F Supplementary Fig. 1. Gating strategy for CD44+CD133+CD24+ B16 tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells.

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

Molecular Therapy - Nucleic Acids

Days after cell inoculation Days after cell inoculation

Days after cell inoculation Days after cell inoculation

Supplementary Figure S1: FGFR4 silencing synergistically enhances the effects of chemotherapy in colon cancer cells. siFGFR4 FGFR4_6 FGFR4_2 Neg Con FGFR4.

BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma Wenjing Fu, Shengguo Yi, Lei.

AE1/AE3 Rabbit Normal IgG Supplementary Figure S1 White bar = 5 mm

Volume 158, Issue 1, Pages (July 2014)

Supplementary Figure 1. Structure of amlexanox

mRNA level as % relative to

Refer to word document for this table

Volume 10, Issue 5, Pages (May 2018)

Relative amount of nuclear β-catenin

Leukocytes in human PDAC

Different responses of healthy, relative healthy and OA chondrocytes with IL1β treatment under hypoxia and normoxia X. Huang, L. Zhong, J. Post, M. Karperien

Bernard et al, Supplementary Figure S1

Fold Change of hsa-miR-3687 (T/N)(log2)

1 Oncomine database: DKK2 upregulation in colorectal cancers(CRC)

Volume 42, Issue 6, Pages (June 2005)

Supplementary Table 1. Summary of surface marker expression of adherent (A) and sphere-forming MRT cell lines (B), and primary tumors (C). A Sample CD146.

Supplementary Figure 1 a b c d e

Hip derived synovial mesenchymal progenitor cell surface markers as indicators for differentiation potential A. Affan, N. Al-Jezani, P. Railton, J. Powell,

Supplementary Figure S1

α-Cells mainly express SSTR2 and SSTR3

Supplemental Figure 1 Cell proliferation (% of mock)

A B C D E F Supplementary Fig. 3. Gating strategy for ES2 ALDHhi tumor initiating cells (TIC). Cells were treated with the specific aldehyde dehydrogenase.

MYC degradation screen identifies a compound that stabilizes MYC protein. MYC degradation screen identifies a compound that stabilizes MYC protein. (A)

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

Increased CCL5 expression, infiltration of Treg cells, and apoptosis of CD8+ T cells in human colorectal tissues. Increased CCL5 expression, infiltration.

LINC00092 binds with PFKFB2 to promote ovarian cancer metastasis.

by Ajoy Aloysius, Ramanuj DasGupta, and Jyotsna Dhawan

EMT gene expression patterns of M-Wnt and E-Wnt cells in vitro and in vivo. EMT gene expression patterns of M-Wnt and E-Wnt cells in vitro and in vivo.

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

Activation of Wnt signaling pathway in trastuzumab-resistant cell lines. Activation of Wnt signaling pathway in trastuzumab-resistant cell lines. A, bar.

Neurotensin and insulin induce increases in CTGF, CYR61, and CXCL5 gene expression and stimulate cell proliferation and colony via YAP/TAZ in PDAC cells.

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

PD-L1 is expressed in breast cancer.

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

Expression of chemokine receptors in A-498 cell line.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells. Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells.

Presentation transcript:

expression surface markers Supplementary S1 A expression surface markers Cell line PATIENT (sex/age) Tumor type CD326 CD3 CD44 CD133 CD117 Pe 4/15 M/72 adeno carcinoma 0% 3% 95% 14% Pe 5/15 M/86 small cell undifferentiated carcinoma 5% B Pe 4/15 Pe 5/15 ALDH Bright cells (%) mRNA expression Pe 4/15 Pe 5/15 C D Pe 4/15 Pe 5/15 % viability SCD1 GAPDH 2D 3D Pe 4/15 Pe 5/15 YAP TAZ Pe 4/15 Pe 5/15

Supplementary S2 A B ** Nuclear YAP/TAZ MF-438 Relative mRNA level **

Supplementary S3 A F E D C B G N M L I H

Supplementary S4 30 µm CTR 18 µm MF-438

Relative mRNA level Axin2 Supplementary S5 YAP TAZ GAPDH SCD1 RLU TOP/FOP-FLASH siCTR siSCD1 RLU 8X-GTIIC B C Relative mRNA level Axin2 Pe 4/15 ** A * YAP TAZ GAPDH CTR C59 D E CTR ** C59 N° spheroids/CTR ** XAV-939

Supplementary S6 A B C D E - WNT + WNT CTR MF-438 ** * N°spheroids/CTR siCTR siYAP/TAZ + WNT - WNT ** Viability (A.U.) * ** * N°spheroids/CTR

Supplementary S7 A B C Relative mRNA level Relative mRNA level ** Relative mRNA level Relative mRNA level Relative mRNA level ** * siCTR siCTR siβ-TrcP+siSCD1 siaxin1+siSCD1

Supplementary S8 scd1/taz scd1/yap scd1/ctgf scd1/birc5 OS MONTHS 1.0 0.8 0.8 0.6 0.6 P=0.024 P=0.013 0.4 0.4 0.2 0.2 Other yap1_low/scd1_low Other taz_low/scd1_low 0.0 0.0 20 40 60 80 100 120 20 40 60 80 100 120 OS scd1/ctgf scd1/birc5 1.0 1.0 0.8 0.8 0.6 0.6 P=0.017 P=0.0004 0.4 0.4 0.2 Other ctgf_low/scd1_low 0.2 Other birc5_low/scd1_low 0.0 0.0 20 40 60 80 100 120 20 40 60 80 100 120 MONTHS

Supplementary S9